A Single Dose, Three-Arm, Placebo-Controlled, Phase I Studyof the Bradykinin B2 Receptor Antagonist Anatibant(LF16-0687Ms) in Patients with Severe Traumatic Brain Injury.

Autor: Anthony Marmarou, Martine Guy, Laine Murphey, Francis Roy, Laure Layani, Jean-Philippe Combal, Claude Marquer
Zdroj: Journal of Neurotrauma; Dec2005, Vol. 22 Issue 12, p1444-1455, 12p
Databáze: Complementary Index